Cargando…

Imidazoles as Potential Anticancer Agents: An Update on Recent Studies

Nitrogen-containing heterocyclic rings are common structural components of marketed drugs. Among these heterocycles, imidazole/fused imidazole rings are present in a wide range of bioactive compounds. The unique properties of such structures, including high polarity and the ability to participate in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Pankaj, LaRosa, Chris, Antwi, Janet, Govindarajan, Rajgopal, Werbovetz, Karl A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307698/
https://www.ncbi.nlm.nih.gov/pubmed/34299488
http://dx.doi.org/10.3390/molecules26144213
_version_ 1783728108632801280
author Sharma, Pankaj
LaRosa, Chris
Antwi, Janet
Govindarajan, Rajgopal
Werbovetz, Karl A.
author_facet Sharma, Pankaj
LaRosa, Chris
Antwi, Janet
Govindarajan, Rajgopal
Werbovetz, Karl A.
author_sort Sharma, Pankaj
collection PubMed
description Nitrogen-containing heterocyclic rings are common structural components of marketed drugs. Among these heterocycles, imidazole/fused imidazole rings are present in a wide range of bioactive compounds. The unique properties of such structures, including high polarity and the ability to participate in hydrogen bonding and coordination chemistry, allow them to interact with a wide range of biomolecules, and imidazole-/fused imidazole-containing compounds are reported to have a broad spectrum of biological activities. This review summarizes recent reports of imidazole/fused imidazole derivatives as anticancer agents appearing in the peer-reviewed literature from 2018 through 2020. Such molecules have been shown to modulate various targets, including microtubules, tyrosine and serine-threonine kinases, histone deacetylases, p53-Murine Double Minute 2 (MDM2) protein, poly (ADP-ribose) polymerase (PARP), G-quadraplexes, and other targets. Imidazole-containing compounds that display anticancer activity by unknown/undefined mechanisms are also described, as well as key features of structure-activity relationships. This review is intended to provide an overview of recent advances in imidazole-based anticancer drug discovery and development, as well as inspire the design and synthesis of new anticancer molecules.
format Online
Article
Text
id pubmed-8307698
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83076982021-07-25 Imidazoles as Potential Anticancer Agents: An Update on Recent Studies Sharma, Pankaj LaRosa, Chris Antwi, Janet Govindarajan, Rajgopal Werbovetz, Karl A. Molecules Review Nitrogen-containing heterocyclic rings are common structural components of marketed drugs. Among these heterocycles, imidazole/fused imidazole rings are present in a wide range of bioactive compounds. The unique properties of such structures, including high polarity and the ability to participate in hydrogen bonding and coordination chemistry, allow them to interact with a wide range of biomolecules, and imidazole-/fused imidazole-containing compounds are reported to have a broad spectrum of biological activities. This review summarizes recent reports of imidazole/fused imidazole derivatives as anticancer agents appearing in the peer-reviewed literature from 2018 through 2020. Such molecules have been shown to modulate various targets, including microtubules, tyrosine and serine-threonine kinases, histone deacetylases, p53-Murine Double Minute 2 (MDM2) protein, poly (ADP-ribose) polymerase (PARP), G-quadraplexes, and other targets. Imidazole-containing compounds that display anticancer activity by unknown/undefined mechanisms are also described, as well as key features of structure-activity relationships. This review is intended to provide an overview of recent advances in imidazole-based anticancer drug discovery and development, as well as inspire the design and synthesis of new anticancer molecules. MDPI 2021-07-11 /pmc/articles/PMC8307698/ /pubmed/34299488 http://dx.doi.org/10.3390/molecules26144213 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sharma, Pankaj
LaRosa, Chris
Antwi, Janet
Govindarajan, Rajgopal
Werbovetz, Karl A.
Imidazoles as Potential Anticancer Agents: An Update on Recent Studies
title Imidazoles as Potential Anticancer Agents: An Update on Recent Studies
title_full Imidazoles as Potential Anticancer Agents: An Update on Recent Studies
title_fullStr Imidazoles as Potential Anticancer Agents: An Update on Recent Studies
title_full_unstemmed Imidazoles as Potential Anticancer Agents: An Update on Recent Studies
title_short Imidazoles as Potential Anticancer Agents: An Update on Recent Studies
title_sort imidazoles as potential anticancer agents: an update on recent studies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307698/
https://www.ncbi.nlm.nih.gov/pubmed/34299488
http://dx.doi.org/10.3390/molecules26144213
work_keys_str_mv AT sharmapankaj imidazolesaspotentialanticanceragentsanupdateonrecentstudies
AT larosachris imidazolesaspotentialanticanceragentsanupdateonrecentstudies
AT antwijanet imidazolesaspotentialanticanceragentsanupdateonrecentstudies
AT govindarajanrajgopal imidazolesaspotentialanticanceragentsanupdateonrecentstudies
AT werbovetzkarla imidazolesaspotentialanticanceragentsanupdateonrecentstudies